ULT Monitoring Frequency — SCE Rheumatology MCQ

Instant feedback + full explanation. One question, done properly.

EasyCrystal ArthropathyULT Monitoring FrequencySCE Rheumatology

A 55-year-old man with gout has started allopurinol as part of a treat-to-target urate-lowering strategy. He is tolerating treatment but has not yet reached his target serum urate level. According to NICE NG219, how often should serum urate be measured to guide dose escalation during titration?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: C — Monthly

The correct answer is C: monthly. NICE recommends starting urate-lowering therapy at a low dose and using monthly serum urate measurements to guide dose increases, as tolerated, until the target serum urate level is reached. The usual target is below 360 micromol/L; a target below 300 micromol/L may be considered for tophi, chronic gouty arthritis, or persistent frequent flares despite a level below 360 micromol/L. Weekly or fortnightly testing is unnecessarily frequent, whereas 6-monthly or annual testing would delay treat-to-target dose adjustment. Annual monitoring is considered only after the target has been achieved in a person continuing urate-lowering therapy.

Reference: National Institute for Health and Care Excellence. NG219: Gout—diagnosis and management, recommendations 1.5.5 and 1.5.15. 2022. https://www.nice.org.uk/guidance/ng219/chapter/Recommendations